GlassScriptPhysician profile
Uzma A Chatha
NPI 1407174451
$2,743.55
in general payments reported to CMS, 2019-2025
20 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $253 · 2021: $389 · 2022: $443 · 2023: $461 · 2024: $595 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $567.64 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $545.01 | 2019-2025 | Farxiga, Breztri |
| Boston Scientific Corporation | $277.68 | 2021-2024 | |
| Amgen INC. | $177.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $164.08 | 2019-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $157.70 | 2019-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $101.00 | 2022-2024 | |
| Exact Sciences Corporation | $99.35 | 2023-2025 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.13 | 2022 | |
| Pfizer INC. | $95.89 | 2019-2023 | |
| Glaxosmithkline, LLC. | $91.88 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.71 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $62.53 | 2020-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $30.06 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.29 | 2024 | Dexcom G6 Transmitter |
| Global Blood Therapeutics, INC. | $15.00 | 2022 | |
| Athena Bioscience, LLC | $13.29 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.00 | 2019 | |
| Allergan, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Chatha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.